Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
1. Determine the maximum tolerable dose (MTD) and / or phase II recommended dose (RP2D) of the allotinib combined mXELIRI protocol. 2. To evaluate the safety and tolerance of the combination of anlotinib and mXELIRI in the second-line treatment of patients with advanced colorectal cancer
创建时间：
2021-07-15
